S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal Article
New nucleoside analogues in clinical development.
Journal ArticleDOI
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.
TL;DR: It is concluded that a quicker TPR predicts longer DFS and OS in patients with ALL, and a short TPR seems to be able to override adverse characteristics in the outcome of ALL patients treated with chemotherapy.
Journal ArticleDOI
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission
Hagop M. Kantarjian,Deborah A. Thomas,Farhad Ravandi,Stefan Faderl,Guillermo Garcia-Manero,J. Shan,Sherry Pierce,Jorge E. Cortes,Susan O'Brien +8 more
TL;DR: The outcome of adults with acute lymphocytic leukemia who achieve a complete response (CR) on salvage therapy is thought to be poor, but not previously analyzed, and the effects of pretreatment factors on prognosis are defined.
Journal ArticleDOI
Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML).
Elias Jabbour,Hagop M. Kantarjian,Ehab Atallah,Gautam Borthakur,William G. Wierda,Stefan Faderl,Steven M. Kornblau,Jorge E. Cortes +7 more
TL;DR: Imatinib dose escalation can induce sustained molecular and cytogenetic responses in patients with failure or suboptimal response to standard-dose imatinib.
Journal ArticleDOI
Anthracycline Dose Intensification in Adult Acute Lymphoblastic Leukemia: Lack of Benefit in the Context of the Fractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Regimen
Deborah A. Thomas,Susan O'Brien,Stefan Faderl,Farhad Ravandi,Elias Jabbour,Sherry Pierce,Jorge E. Cortes,Hagop M. Kantarjian +7 more
TL;DR: This study was conducted to evaluate whether addition of anthracycline‐based consolidation chemotherapy (Course 2) with liposomal daunorubicin and cytarabine to the standard hyper‐CVAD regimen would improve outcome.